Publicaciones (10) Publicaciones de Laura Blanco Fernández

2024

  1. A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies

    British Journal of Haematology

  2. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  3. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2021

  1. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  2. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

2020

  1. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2019

  1. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

2017

  1. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

    International Journal of Pharmaceutics, Vol. 533, Núm. 1, pp. 236-244